As of November 10, 2026, 12 holders' latest Schedule 13D or 13G filings report owning 5% or more of Beta Bionics, Inc. The largest reported stake is T. Rowe Price Associates, Inc.'s, at 16.6%. 25 filings are on record since August 7, 2025 (Schedule 13G, October 7, 2026).
Sell to companies like Beta Bionics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Soleus Private Equity Fund II, L.P. · Sole voting: 0 · Shared voting: 1,003,961 · Sole dispositive: 0 · Shared dispositive: 1,003,961 · SCHEDULE 13G/A, 2026-11-09
- · Reporting person: T. Rowe Price Associates, Inc. · Sole voting: 8,939,271 · Shared voting: 0 · Sole dispositive: 8,943,061 · Shared dispositive: 0 · SCHEDULE 13G, 2026-10-07
- · Reporting person: Farallon Capital Management, L.L.C. · Sole voting: 0 · Shared voting: 595,000 · Sole dispositive: 0 · Shared dispositive: 595,000 · SCHEDULE 13G/A, 2026-08-13
- · Reporting person: Divisadero Street Capital Management, LP · Sole voting: 0 · Shared voting: 3,072,985 · Sole dispositive: 0 · Shared dispositive: 3,072,985 · SCHEDULE 13G, 2026-07-24
- · Holder: RTW Investments, LP · Percent: 4.5% · SCHEDULE 13G/A
Beta Bionics, Inc. has 25 Schedule 13D or 13G filings on record since 2025-08-07. 12 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| T. Rowe Price Associates, Inc. | 16.6% | 8,943,061 | SCHEDULE 13G, 2026-10-07 | 2026-09-30 |
| Eventide Asset Management, LLC | 13.4% | 5,945,488 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| 9.9% | 4,313,920 | SCHEDULE 13G/A, 2025-11-12 | 2025-09-30 | |
| 9.8% | 4,354,501 | SCHEDULE 13G/A, 2026-05-08 | 2026-03-31 | |
| 8.7% | 4,828,619 | SCHEDULE 13G/A, 2026-11-09 | 2026-09-30 | |
| 8.6% | 3,739,567 | SCHEDULE 13G/A, 2025-11-07 | 2025-09-30 | |
| Sands Capital Life Sciences Pulse Fund II. L.P. | 8.2% | 3,570,113 | SCHEDULE 13G/A, 2025-08-13 | 2025-06-30 |
| 8.1% | 3,607,920 | SCHEDULE 13G/A, 2026-05-12 | 2026-03-31 | |
| Divisadero Street Capital Management, LP | 6.9% | 3,072,985 | SCHEDULE 13G, 2026-07-24 | 2026-07-17 |
| BlackRock, Inc. | 6.4% | 2,778,764 | SCHEDULE 13G, 2025-10-17 | 2025-09-30 |
| 5.8% | 2,534,565 | SCHEDULE 13G/A, 2026-02-12 | 2025-12-31 | |
| Point72 Asset Management, L.P. | 5.2% | 2,290,023 | SCHEDULE 13G, 2026-02-23 | 2026-02-18 |
| RTW Investments, LP | 4.5% | 2,000,000 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Perceptive Advisors LLC | 3.68% | 1,593,608 | SCHEDULE 13G/A, 2025-08-07 | 2025-03-31 |
| Millennium Management LLC | 1.8% | 796,964 | SCHEDULE 13G/A, 2025-10-16 | 2025-09-30 |
| Farallon Capital Management, L.L.C. | 1.3% | 595,000 | SCHEDULE 13G/A, 2026-08-13 | 2026-06-30 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-26 | 2026-03-13 |
| Wellington Management Group LLP | 0% | 0 | SCHEDULE 13G/A, 2026-02-10 | 2025-12-31 |
| Wellington Hadley Harbor Aggregator IV, L.P. | 0% | 0 | SCHEDULE 13G/A, 2026-02-10 | 2025-12-31 |
Holding shares or following this stake? See who's behind Beta Bionics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Beta Bionics, Inc. and the records around it.
Beta Bionics, Inc. elsewhere on the record
- IPO filing Jan 2025
- Who owns it
Companies that share a holder
- Sands Capital Life Sciences Pulse Fund II. L.P. also filed stake reports on 3 other companies: Acrivon Therapeutics, Inc. (Aug 2026), Inhibikase Therapeutics, Inc. (Aug 2026), Alamar Biosciences, Inc. (Jul 2026)
- Eventide Asset Management, LLC also filed stake reports on 9 other companies: Immix Biopharma, Inc. (Aug 2026), Ovid Therapeutics Inc. (Aug 2026), COLLEGIUM PHARMACEUTICAL, INC (May 2026)
- Farallon Capital Management, L.L.C. also filed stake reports on 18 other companies: ENANTA PHARMACEUTICALS INC (Aug 2026), EXELIXIS, INC. (Aug 2026), InflaRx N.V. (Aug 2026)
Watch Beta Bionics, Inc.
Get an email when Beta Bionics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Beta Bionics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Beta Bionics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Beta Bionics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
30 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| T. Rowe Price Associates, Inc. | 8,939,271 | 0 | 8,943,061 | 0 | SCHEDULE 13G, 2026-10-07 |
| Soleus Private Equity Fund II, L.P. | 0 | 1,003,961 | 0 | 1,003,961 | SCHEDULE 13G/A, 2026-11-09 |
| Soleus Private Equity GP II, LLC | 0 | 1,003,961 | 0 | 1,003,961 | SCHEDULE 13G/A, 2026-11-09 |
| Soleus PE GP II, LLC | 0 | 1,003,961 | 0 | 1,003,961 | SCHEDULE 13G/A, 2026-11-09 |
| Soleus Capital Master Fund, L.P. | 0 | 3,783,237 | 0 | 3,783,237 | SCHEDULE 13G/A, 2026-11-09 |
| Soleus Capital, LLC | 0 | 3,783,237 | 0 | 3,783,237 | SCHEDULE 13G/A, 2026-11-09 |
| Soleus Capital Group, LLC | 0 | 3,783,237 | 0 | 3,783,237 | SCHEDULE 13G/A, 2026-11-09 |
| Soleus Capital Management, L.P. | 0 | 4,787,198 | 0 | 4,787,198 | SCHEDULE 13G/A, 2026-11-09 |
| Soleus GP, LLC | 0 | 4,787,198 | 0 | 4,787,198 | SCHEDULE 13G/A, 2026-11-09 |
| Levy Guy | 41,421 | 4,787,198 | 41,421 | 4,787,198 | SCHEDULE 13G/A, 2026-11-09 |
| Divisadero Street Capital Management, LP | 0 | 3,072,985 | 0 | 3,072,985 | SCHEDULE 13G, 2026-07-24 |
| William Zolezzi | 0 | 3,072,985 | 0 | 3,072,985 | SCHEDULE 13G, 2026-07-24 |
| Divisadero Street Partners, L.P. | 0 | 2,612,985 | 0 | 2,612,985 | SCHEDULE 13G, 2026-07-24 |
| Divisadero Street Partners GP, LLC | 0 | 2,612,985 | 0 | 2,612,985 | SCHEDULE 13G, 2026-07-24 |
| Divisadero Street Capital, LLC | 0 | 3,072,985 | 0 | 3,072,985 | SCHEDULE 13G, 2026-07-24 |
| Farallon Capital Management, L.L.C. | 0 | 595,000 | 0 | 595,000 | SCHEDULE 13G/A, 2026-08-13 |
| Zone Healthcare Holdings, LLC | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-13 |
| Farallon Capital Partners, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-13 |
| Farallon Capital Institutional Partners, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-13 |
| Farallon Capital Institutional Partners II, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-13 |
| Farallon Capital Institutional Partners III, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-13 |
| Four Crossings Institutional Partners V, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-13 |
| Farallon Capital Offshore Investors II, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-13 |
| Farallon Capital (AM) Investors, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-13 |
The latest filing identifies Beta Bionics, Inc. by CUSIP 08659B102 and gives its principal executive office as 11 Hughes, Irvine, CA 92618 (SCHEDULE 13G/A, 2026-11-09).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-07 | Morgan Stanley | 6.8% | SCHEDULE 13G |
| 2025-08-07 | Perceptive Advisors LLC | 3.68% | SCHEDULE 13G/A |
| 2025-08-13 | Dapice Joshua J. | 9.7% | SCHEDULE 13G/A |
| 2025-08-13 | Sands Capital Life Sciences Pulse Fund II. L.P. | 8.2% | SCHEDULE 13G/A |
| 2025-09-19 | Millennium Management LLC | 5.3% | SCHEDULE 13G |
| 2025-10-16 | Millennium Management LLC | 1.8% | SCHEDULE 13G/A |
| 2025-10-17 | BlackRock, Inc. | 6.4% | SCHEDULE 13G |
| 2025-10-30 | The Vanguard Group | 5.09% | SCHEDULE 13G |
| 2025-11-07 | Morgan Stanley | 8.6% | SCHEDULE 13G/A |
| 2025-11-12 | Dapice Joshua J. | 9.9% | SCHEDULE 13G/A |
| 2026-02-09 | Dapice Joshua J. | 9.9% | SCHEDULE 13G/A |
| 2026-02-10 | Wellington Management Group LLP | 0% | SCHEDULE 13G/A |
| 2026-02-10 | Wellington Hadley Harbor Aggregator IV, L.P. | 0% | SCHEDULE 13G/A |
| 2026-02-12 | Guy Levy | 5.8% | SCHEDULE 13G/A |
| 2026-02-17 | RTW Investments, LP | 5.7% | SCHEDULE 13G/A |
| 2026-02-23 | Point72 Asset Management, L.P. | 5.2% | SCHEDULE 13G |
| 2026-03-26 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-05-08 | Levy Guy | 9.8% | SCHEDULE 13G/A |
| 2026-05-12 | Dapice Joshua J. | 8.1% | SCHEDULE 13G/A |
| 2026-05-15 | RTW Investments, LP | 4.5% | SCHEDULE 13G/A |
| 2026-05-15 | Eventide Asset Management, LLC | 13.4% | SCHEDULE 13G/A |
| 2026-07-24 | Divisadero Street Capital Management, LP | 6.9% | SCHEDULE 13G |
| 2026-08-13 | Farallon Capital Management, L.L.C. | 1.3% | SCHEDULE 13G/A |
| 2026-10-07 | T. Rowe Price Associates, Inc. | 16.6% | SCHEDULE 13G |
| 2026-11-09 | Levy Guy | 8.7% | SCHEDULE 13G/A |
Questions about who owns Beta Bionics, Inc.
Who owns Beta Bionics, Inc.?
On this page, 12 holders' latest ownership filings report 5% or more of Beta Bionics, Inc.: T. Rowe Price Associates, Inc. (16.6%, Schedule 13G, filed 2026-10-07), Eventide Asset Management, LLC (13.4%, Schedule 13G/A, filed 2026-05-15), Dapice Joshua J. (9.9%, Schedule 13G/A, filed 2025-11-12), Levy Guy (9.8%, Schedule 13G/A, filed 2026-05-08) and Levy Guy (8.7%, Schedule 13G/A, filed 2026-11-09); 7 more are listed above.
Who are the largest shareholders of Beta Bionics, Inc.?
By the share each holder's latest filing reports, the largest holders of Beta Bionics, Inc. on this page are T. Rowe Price Associates, Inc. (16.6%), Eventide Asset Management, LLC (13.4%) and Dapice Joshua J. (9.9%).
When did T. Rowe Price Associates, Inc. buy into Beta Bionics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from T. Rowe Price Associates, Inc. on this page is the Schedule 13G, filed 2026-10-07, reporting 16.6%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 25 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Beta Bionics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| January 31, 2025 | IPO filing, Form 424B4 | $17 a share | IPO filings | Source |
| January 28, 2025 | IPO filing, Form S-1/A | $16 to $17 a share | IPO filings | Source |
| January 23, 2025 | IPO filing, Form S-1/A | $14 to $16 a share | IPO filings | Source |
| January 22, 2025 | IPO filing, Form S-1/A | $14 to $16 a share | IPO filings | Source |
| January 6, 2025 | IPO filing, Form S-1 | — | IPO filings | Source |
Tools for this story
Each opens in a new tab, filled in for Beta Bionics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.